Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy

Carcinogenesis

Volumn 31, Issue 6, 2010, Pages 984-993

  Varin, Emilie ^a   Denoyelle, Christophe ^a   Brotin, Emilie ^a   Meryet Figuière, Matthieu ^a   Giffard, Florence ^a   Abeilard, Edwige ^a   Goux, Didier ^b   Gauduchon, Pascal ^a   Icard, Philippe ^a,c   Poulain, Laurent ^a  

^a Centre de Lutte Contre le Cancer F Baclesse   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; DRUG EFFECT; MESOTHELIOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; HUMANS; MESOTHELIOMA; MICROSCOPY, ELECTRON, TRANSMISSION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77953926671     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq026     Document Type: Article

References (44)

1. Cugell,D.W. et al. (2004) Asbestos and the pleura: a review. Chest, 125, 1103-1117.
2. Tsao,A.S. et al. (2009) Malignant pleural mesothelioma. J. Clin. Oncol., 27, 2081-2090.
3. Kelland,L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 7, 573-584.
4. Fulda,S. et al. (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25, 4798-4811.
5. Redmond,K.M. et al. (2008) Resistance mechanisms to cancer chemotherapy. Front. Biosci., 13, 5138-5154.
6. Walensky,L.D. (2006) BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ., 13, 1339-1350.
7. Youle,R.J. et al. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol., 9, 47-59.
8. Yip,K.W. et al. (2008) Bcl-2 family proteins and cancer. Oncogene, 27, 6398-6406.
9. Kirkin,V. et al. (2004) The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta, 1644, 229-249.
10. Soini,Y. et al. (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res., 5, 3508-3515.
11. O'Kane,S.L. et al. (2006) Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol., 45, 449-453.
12. Letai,A.G. (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer, 8, 121-132.
13. Smythe,W.R. et al. (2002) Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J. Thorac. Cardiovasc. Surg., 123, 1191-1198.
14. Hopkins-Donaldson,S. et al. (2003) Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int. J. Cancer, 106, 160-166.
15. Ozvaran,M.K. et al. (2004) Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol. Cancer Ther., 3, 545-550.
16. Littlejohn,J.E. et al. (2008) Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int. J. Cancer, 123, 202-208.
17. Yeow,W.S. et al. (2006) Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Thorac. Cardiovasc. Surg., 132, 1356-1362.
18. Cao,X. et al. (2007) Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol. Ther., 6, 246-252.
19. Willis,S.N. et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev., 19, 1294-1305.
20. Kabeya,Y. et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J., 19, 5720-5728.
21. Jiang,M. et al. (2006) Regulation of PUMA-alpha by p53 in cisplatininduced renal cell apoptosis. Oncogene, 25, 4056-4066.
22. Zhang,L.J. et al. (2008) Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anticancer Drugs, 19, 159-166.
23. Ramalingam,S.S. et al. (2008) Recent advances in the treatment of malignant pleural mesothelioma. J. Thorac. Oncol., 3, 1056-1064.
24. Villanova,F. et al. (2008) Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies. Curr. Med. Chem., 15, 631-641.
25. Fennell,D.A. et al. (2004) Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol., 5, 354-362.
26. Zhang,X. et al. (2009) Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res., 29, 1249-1254.
27. Leist,M. et al. (1997) Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med., 185, 1481-1486.
28. Gramaglia,D. et al. (2004) Apoptosis to necrosis switching downstream of apoptosome formation requires inhibition of both glycolysis and oxidative phosphorylation in a BCL-X(L)and PKB/AKT-independent fashion. Cell Death Differ., 11, 342-353.
29. Sato,T. et al. (2008) Apoptosis supercedes necrosis in mitochondrial DNA-depleted Jurkat cells by cleavage of receptor-interacting protein and inhibition of lysosomal cathepsin. J. Immunol., 181, 197-207.
30. Gordon,G.J. et al. (2002) Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis, 23, 1017-1024.
31. Hirsch,T. et al. (1997) The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene, 15, 1573-1581.
32. Yang,C. et al. (2007) Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am. J. Physiol. Renal Physiol., 292, F1710-F1717.
33. Willis,S.N. et al. (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol., 17, 617-625.
34. Roos,W.P. et al. (2006) DNA damage-induced cell death by apoptosis. Trends Mol. Med., 12, 440-450.
35. Hauck,P. et al. (2009) Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol. Cancer Ther., 8, 883-892.
36. Herrant,M. et al. (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene, 23, 7863-7873.
37. Song,L. et al. (2005) Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther., 4, 267-276.
38. van Delft,M.F. et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 10, 389-399.
39. Chen,S. et al. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res., 67, 782-791.
40. Tahir,S.K. et al. (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res., 67, 1176-1183.
41. Brotin,E. et al. (2010) Bcl-x(L) and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer, 126(4), 885-895.
42. Mohammad,R. et al. (2008) Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Pat. Anticancer Drug Discov., 3, 20-30.
43. Gondi,C.S. et al. (2009) Concepts in in vivo siRNA delivery for cancer therapy. J. Cell. Physiol., 220, 285-291.
44. Grimm,D. (2009) Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev., 61, 672-703.